BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pellegrini C, Martelli A, Antonioli L, Fornai M, Blandizzi C, Calderone V. NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications. Med Res Rev 2021;41:1890-926. [PMID: 33460162 DOI: 10.1002/med.21781] [Cited by in Crossref: 4] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Koca-ünsal RB, Şehirli AÖ, Sayıner S, Aksoy U. Relationship of NLRP3 inflammasome with periodontal, endodontic and related systemic diseases. Mol Biol Rep. [DOI: 10.1007/s11033-022-07894-0] [Reference Citation Analysis]
2 Anderson P, Kokole D, Jané Llopis E, Burton R, Lachenmeier DW. Lower Strength Alcohol Products—A Realist Review-Based Road Map for European Policy Making. Nutrients 2022;14:3779. [DOI: 10.3390/nu14183779] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Bikomeye JC, Terwoord JM, Santos JH, Beyer AM. Emerging mitochondrial signaling mechanisms in cardio-oncology: beyond oxidative stress. Am J Physiol Heart Circ Physiol 2022. [PMID: 35930448 DOI: 10.1152/ajpheart.00231.2022] [Reference Citation Analysis]
4 Lin W, Li L, Hsiao Y, Wong W, Chiu H, Hsu H, Peng Y, Ho C, Chernikov OV, Cheng S, Yang S, Hua K. Repositioning of the Angiotensin II Receptor Antagonist Candesartan as an Anti-Inflammatory Agent With NLRP3 Inflammasome Inhibitory Activity. Front Immunol 2022;13:870627. [DOI: 10.3389/fimmu.2022.870627] [Reference Citation Analysis]
5 Bakhshi S, Shamsi S. MCC950 in the treatment of NLRP3-mediated inflammatory diseases: Latest evidence and therapeutic outcomes. International Immunopharmacology 2022;106:108595. [DOI: 10.1016/j.intimp.2022.108595] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
6 Gong W, Zhang S, Chen Y, Shen J, Zheng Y, Liu X, Zhu M, Meng G. Protective role of hydrogen sulfide against diabetic cardiomyopathy via alleviating necroptosis. Free Radical Biology and Medicine 2022;181:29-42. [DOI: 10.1016/j.freeradbiomed.2022.01.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Bal NB, Bostancı A, Sadi G, Dönmez MO, Uludağ MO, Demirel-yilmaz E. Resveratrol and regular exercise may attenuate hypertension-induced cardiac dysfunction through modulation of cellular stress responses. Life Sciences 2022. [DOI: 10.1016/j.lfs.2022.120424] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Hua F, Shi L, Zhou P. Phenols and terpenoids: natural products as inhibitors of NLRP3 inflammasome in cardiovascular diseases. Inflammopharmacology 2022. [PMID: 35039992 DOI: 10.1007/s10787-021-00918-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
9 Pellegrini C, D'Antongiovanni V, Miraglia F, Rota L, Benvenuti L, Di Salvo C, Testa G, Capsoni S, Carta G, Antonioli L, Cattaneo A, Blandizzi C, Colla E, Fornai M. Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson's disease before brain pathology. NPJ Parkinsons Dis 2022;8:9. [PMID: 35022395 DOI: 10.1038/s41531-021-00263-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Pellegrini C, Antonioli L, Lopez-Castejon G, Bertinaria M. Editorial: Neurological, Metabolic and Inflammatory Disorders: A Common Root in Inflammasome. Front Pharmacol 2021;12:808400. [PMID: 34950043 DOI: 10.3389/fphar.2021.808400] [Reference Citation Analysis]
11 Wang B, Qiu J, Lian J, Yang X, Zhou J. Gut Metabolite Trimethylamine-N-Oxide in Atherosclerosis: From Mechanism to Therapy. Front Cardiovasc Med 2021;8:723886. [PMID: 34888358 DOI: 10.3389/fcvm.2021.723886] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
12 Guo L, Qin G, Cao Y, Yang Y, Dai S, Wang L, Wang E. Regulation of the Immune Microenvironment by an NLRP3 Inhibitor Contributes to Attenuation of Acute Right Ventricular Failure in Rats with Pulmonary Arterial Hypertension. J Inflamm Res 2021;14:5699-711. [PMID: 34754216 DOI: 10.2147/JIR.S336964] [Reference Citation Analysis]
13 Nilsson J, Shah PK. Promoting athero-protective immunity by vaccination with low density lipoprotein-derived antigens. Atherosclerosis 2021;335:89-97. [PMID: 34462127 DOI: 10.1016/j.atherosclerosis.2021.08.033] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Gastaldi S, Boscaro V, Gianquinto E, Sandall CF, Giorgis M, Marini E, Blua F, Gallicchio M, Spyrakis F, MacDonald JA, Bertinaria M. Chemical Modulation of the 1-(Piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazole-2-one Scaffold as a Novel NLRP3 Inhibitor. Molecules 2021;26:3975. [PMID: 34209843 DOI: 10.3390/molecules26133975] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
15 Ding Y, Gong W, Zhang S, Shen J, Liu X, Wang Y, Chen Y, Meng G. Protective role of sirtuin3 against oxidative stress and NLRP3 inflammasome in cholesterol accumulation and foam cell formation of macrophages with ox-LDL-stimulation. Biochem Pharmacol 2021;192:114665. [PMID: 34181898 DOI: 10.1016/j.bcp.2021.114665] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
16 Özenver N, Efferth T. Phytochemical inhibitors of the NLRP3 inflammasome for the treatment of inflammatory diseases. Pharmacol Res 2021;170:105710. [PMID: 34089866 DOI: 10.1016/j.phrs.2021.105710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]